TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples